Related Experiment Video
Updated: Feb 28, 2026

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
Published on: December 16, 2022
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T Le1,2,3, Jennifer N Durham1,2,3, Kellie N Smith1,3
1Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD 21287, USA.
Abstract:
The genomes of cancers deficient in mismatch repair contain exceptionally high numbers of somatic mutations. In a proof-of-concept study, we previously showed that colorectal cancers with mismatch repair deficiency were sensitive to immune checkpoint blockade with antibodies to programmed death receptor-1 (PD-1). We have now expanded this study to evaluate the efficacy of PD-1 blockade in patients with advanced mismatch repair-deficient cancers across 12 different tumor types. Objective radiographic responses were observed in 53% of patients, and complete responses were achieved in 21% of patients. Responses were durable, with median progression-free survival and overall survival still not reached. Functional analysis in a responding patient demonstrated rapid in vivo expansion of neoantigen-specific T cell clones that were reactive to mutant neopeptides found in the tumor. These data support the hypothesis that the large proportion of mutant neoantigens in mismatch repair-deficient cancers make them sensitive to immune checkpoint blockade, regardless of the cancers' tissue of origin.
Insights
Mismatch repair deficient cancers, with many mutations, show high response rates to programmed death receptor-1 (PD-1) blockade. This immunotherapy approach is effective across various cancer types, offering durable patient benefits.
Area of Science:
- Oncology
- Immunology
- Genetics
Background:
- Cancers with mismatch repair deficiency exhibit a high mutation burden.
- Previous studies indicated sensitivity of mismatch repair deficient colorectal cancers to PD-1 blockade.
Purpose of the Study:
- To evaluate the efficacy of programmed death receptor-1 (PD-1) blockade in patients with advanced mismatch repair-deficient cancers across diverse tumor types.
Main Methods:
- Expanded a proof-of-concept study on PD-1 blockade efficacy.
- Included patients with advanced mismatch repair-deficient cancers from 12 tumor types.
- Assessed radiographic responses, progression-free survival, and overall survival.
Main Results:
- Objective radiographic responses observed in 53% of patients.
- Complete responses achieved in 21% of patients.
- Responses were durable, with median progression-free and overall survival not reached.
Conclusions:
- Mismatch repair-deficient cancers are sensitive to PD-1 blockade, irrespective of tumor origin.
- High neoantigen load in these cancers likely drives sensitivity to immune checkpoint blockade.
- PD-1 blockade represents a promising therapeutic strategy for mismatch repair-deficient cancers.
Related Concept Videos
Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Mismatch Repair
Abnormal Proliferation
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle

